Peptide name : WP1

Source/Organism : Derived from RLL peptide

Linear/Cyclic : Cyclic(M6-M10)

Chirality : L

Peptide length: 14

C-terminal modification: Cyclic(M6-M10)

N-terminal modification : Hydroxamic acid

Non-natural peptide information:

Assay type : HDAC inhibition assay

Assay time : Not Available

Activity : IC50 = 0.310±0.064 µM

Cell line : HeLa

Cancer type : Cervical Cancer

Other activity : Anticancer

Amino acid composition bar chart :

Molecular mass : 1871.4774 Dalton

Aliphatic index : 1.671

Instability index : 45.1714

Hydrophobicity (GRAVY) : 0.4286

Isoelectric point : 12

Charge (pH 7) : 4.7601

Aromaticity : 0

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 1.8

hydrophobic moment : -0.097

Missing amino acid : A,C,D,E,F,G,H,I,K,N,P,Q,S,T,V,W,Y

Most occurring amino acid : L

Most occurring amino acid frequency : 6

Least occurring amino acid : M

Least occurring amino acid frequency : 3

Secondary structure fraction (Helix, Turn, Sheet): (64., 0, 42.)

SMILES Notation: CSCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O

1 : Du L, et al. Development of sulfonium tethered peptides conjugated with HDAC inhibitor to improve selective toxicity for cancer cells. Bioorg Med Chem. 2023; 83:117213. doi: 10.1016/j.bmc.2023.117213

Paper title : Development of sulfonium tethered peptides conjugated with HDAC inhibitor to improve selective toxicity for cancer cells.

Doi : https://doi.org/10.1016/j.bmc.2023.117213

Abstract : The anti-cancer peptides emerged as new weapons for cancer therapy due to their potent toxicity toward various cancer cells. However, their therapeutic promise is often limited by non-specific toxicity to normal cells. How to improve peptides' selectivity to cancer cells is always a matter to solve. In this manuscript, we designed a sulfonium tethered lytic peptide conjugated with a HDAC inhibitor to improve the selectivity of cancer cells. The sulfonium tethered lytic peptide with improved hydrophilicity and positive charge showed reduced toxicity to both cancer cells and normal cells. When conjugated with the HDAC inhibitor, this peptide showed increased toxicity to cancer cells. Besides, the stabilized peptide HDAC conjugate showed better serum stability than the linear peptide conjugate. For cellular function, the stabilized peptide conjugate could induce cancer cell apoptosis, cell cycle arrest, and influence multiple signal pathways through transcriptome analysis. This design may provide an alternative approach for the development of safe and effective anti-cancer drugs.